12-month uptake of PD-L1 testing and atezolizumab (atezo) + nab-paclitaxel (nab-pac) treatment in metastatic triple-negative breast cancer (mTNBC) following accelerated FDA-approval in the United States.

Leisha A. Emens,Christopher Craggs,Marcio Debiasi,Matthew Kent,Patricia Luhn,Erika Paige Hamilton

12-month uptake of PD-L1 testing and atezolizumab (atezo) + nab-paclitaxel (nab-pac) treatment in metastatic triple-negative breast cancer (mTNBC) following accelerated FDA-approval in the United States.

2020

Leisha A. Emens
Christopher Craggs
Marcio Debiasi
Matthew Kent
Patricia Luhn
Erika Paige Hamilton

e13103Background: In March 2019, atezo + nab-pac received accelerated FDA-approval for the treatment (tx) of patients (pts) with unresectable locally advanced or metastatic TNBC who express PD-L1 i...

Keywords:

Atezolizumab
Oncology
PD-L1
Triple-negative breast cancer
fda approval
Pathology
Nab-paclitaxel
Medicine
Internal medicine
locally advanced

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations